Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome
Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome
复制标题
DOI：
10.1016/s0022-5347(05)67972-4
复制
发表时间：
2000-01-01
影响因子：
6.6
通讯作者：
Herr, HW
中科院分区：
文献类型：
--
作者：
Herr, HW
目的：观察随访15~20年的高级别Ta膀胱肿瘤患者的肿瘤进展和生存情况。材料和方法：对148例Ta膀胱肿瘤和73例T1多发、复发的乳头状膀胱肿瘤患者进行评估。所有患者均行完整的经尿道电切术，并接受1个或1个以上疗程的卡介苗治疗。至少随访15年。结果：23例低级别Ta肿瘤15年无进展生存率为95%，无一例死于疾病，125例高级别Ta肿瘤无进展生存率和疾病特异性生存率分别为61%和74%，而高级别Ta肿瘤患者分别为44%和62%。结论：与T1肿瘤患者相似，高级别Ta肿瘤患者有疾病分期进展和死于膀胱癌的终生风险。
Purpose: Tumor progression and survival of patients with high grade Ta bladder tumors followed for 15 to 20 years were evaluated.Materials and Methods: A total of 148 patients with Ta and 73 with T1 multiple, recurrent papillary bladder tumors were evaluated. In all patients complete transurethral resection was performed and 1 or more courses of bacillus Calmette-Guerin therapy were given. Minimum followup was 15 years. Of the Ta tumors 125 were high grade and 23 were low grade, The end points of the study were stage progression, defined as lamina propria invasion, muscle invasion or metastasis, and disease specific survival,Results: The 15-year progression-free survival rate was 95% in the 23 patients with low grade Ta tumors and none died of disease, Progression-free survival and disease specific survival rates were 61% and 74%, respectively, in 125 patients with high grade Ta tumors compared to 44% and 62%, respectively, in 73 with T1 tumors,Conclusions: Patients with high grade Ta tumors have a lifelong risk of disease stage progression and death from bladder cancer similar to these with T1 tumors.